home > news > detailed info


Integrated manufacturing specialist makes series of appointments across Europe

ACG Capsules, one of the largest manufacturers of empty hard capsules (part of the ACG Group), demonstrated its commitment to European expansion by completing a series of appointments across the region.

The announcement follows the appointment of Steven Facer as Vice President - Europe, who was brought in to strengthen the ACG Capsules sales and customer support teams - providing proximity for European customers. To serve the European market better, ACG will also be investing more in enhancing the capacity of its manufacturing facility in Croatia.

The recent appointments in Western Europe include Wayne Camarco as sales manager UK, Ireland and Scandinavia. Wayne has been brought in to support existing customers and new business development. He has well over 20 years' experience in the pharmaceutical and fine chemicals industry, first in R&D with Rhone Poulenc in the US and France and later in technical sales for Ashland Specialty Ingredients in the US.

Wayne will report into the Western European team lead, Hans Moxter, who was brought into the business towards the end of 2016. He commented: "We'd like to welcome Wayne to the team, which has grown significantly over the last year. His experience and contacts will prove invaluable as we continue on our growth trajectory."

In Eastern Europe Denis Balazinec has been promoted to sales associate, to help build and develop business in the region. And Mario Sasek has recently completed his training to become fully operational in providing technical support on machine trials. They will report into Snjezana Sirovec, who manages the Eastern regional team. She said: "ACG is adding deeper layers of expertise to its business. It is excellent to be working alongside such high calibre individuals to deliver valued products and solutions across this growing region."

Steven Facer added: "As an established business and the second largest capsule maker in the world, ACG has always had a strong foothold in Europe. We are now keen to accelerate our growth, and to build long-term relations to serve our customers better. Our proximity to customers and combined industry knowledge is creating great feedback. In the current market, ACG offers quality capsules and other manufacturing solutions throughout the supply chain for the pharmaceutical and nutraceutical sector. We offer prompt local support with consistent pricing which gives ACG the right positioning to leverage opportunities in the region. The market is ripe for growth."

In addition to capsules, ACG is a one-stop shop offering integrated manufacturing, packaging and R&D solutions to the global pharmaceutical industry, integrating businesses right from granulation & coating equipment (ACG Engineering); capsule filling machines (ACG Engineering); tablet compression systems to tablet tooling (both through ACG Engineering); barrier packaging films (ACG Films & Foils) to blister & cartoning machines (ACG Engineering); vision inspection systems (ACG Inspection) to end-of-line machines (ACG Engineering).


About ACG

The ACG group is the only supplier in the world offering integrated manufacturing solutions for the pharmaceutical industry. The company’s diverse product range of Capsules, Films & Foils, Engineering and Inspection systems don’t just meet, but exceeds the demands of international regulatory requirements. ACG is committed to just one goal: to offer everything needed for efficient capsule and tablet manufacturing.

ACG has over 5 decades of experience and is present in over 100 countries, with over 4,500 employees around the world. Our customer-centric approach has won us many loyal, satisfied customers and partners by nurturing relationships with dignity and transparency.

For media enquiries

Madhurima Chakraborty
Corporate Marketing – ACG Worldwide

Tanya Grover
Corporate Marketing- ACG Worldwide

Publicite Ltd
Katrina Suppiah
T: +44 (0) 208 543 6582
Print this page
Send to a friend
News and Press Releases

BioIVT to Focus on the Application of In Vitro Hepatocyte Models in Toxicology Research at the North American ISSX Meeting

BioIVT, a leading provider of research models and services for drug development, today announced that it will be participating in several sessions at the 22nd North American International Society for the Study of Xenobiotics (ISSX) Meeting. This conference will be held from July 15-19 at the Palais des congrès de Montréal in Montréal, Canada.
More info >>

White Papers

Clinical Trial Site Contracting: The Conservative, Progressive and Hybrid Models


For the last 20 years, pharmaceutical companies have turned to a variety of clinical outsourcing solutions to reduce costs and improve timelines, enabling them to focus on their core value of research and development. In today’s tightly competitive market, companies are constantly striving for ways to further cut costs and reduce study startup cycle times, while maintaining quality. One of the key cost factors in global R&D spending, estimated at around $102 billion per Kalorama market research, is the cost of conducting clinical trials. CRO’s, which account for about 30% of the total R&D spending, have risen to the challenge of the clinical, technical and administrative management of these trials. But some pharmaceutical companies question how much control to relinquish to vendor partners, especially in the legal arena, due to potential ramifications.
More info >>

Industry Events

6th Annual Single Cell Analysis Congress

8-9 November 2018, London, UK

Oxford Global is proud to present its 6th Annual Single Cell Analysis Congress taking place on 8-9 November 2018 in London.  Part of the Genomics & Synthetic Biology Series UK, the congress will bring together over 600 end users representing internationally renowned research & academic institutions, clinical research institutions, healthcare organisations as well as leading pharmaceutical and biotech companies.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement